A legal battle that began during the height of the COVID-19 pandemic has entered another significant phase.
The group that successfully forced the U.S. Food and Drug Administration (FDA) to release millions of pages of records related to the approval of the Pfizer-BioNTech COVID-19 vaccine is now asking a federal court to order the agency to pay more than $867,000 in attorneys’ fees and litigation costs.
The request follows years of litigation over access to vaccine approval documents and could establish another important precedent regarding government transparency under the Freedom of Information Act (FOIA).
Why the Lawsuit Began
The dispute dates back to 2021 when Public Health and Medical Professionals for Transparency filed a FOIA request seeking records used by the FDA to approve the Pfizer-BioNTech COVID-19 vaccine.
Initially, the FDA argued that processing the enormous volume of documents would take decades under its normal review schedule.
A federal judge rejected that timeline and ordered the agency to dramatically accelerate production, ultimately leading to the release of more than 1.8 million pages of vaccine-related records over several years.
Why the Plaintiffs Want Legal Fees
Now that the document production is largely complete, the plaintiffs argue they are entitled to recover the legal costs incurred while compelling the FDA to comply.
According to court filings, attorneys representing the group say they spent nearly 1,500 billable hours litigating the matter.
The filing seeks:
- More than $867,000 in attorneys’ fees and litigation expenses
- An enhancement of those fees because of the complexity and significance of the case
- A judicial finding criticizing what they characterize as unreasonable resistance by the FDA during the litigation
The attorneys also disclosed that part of any recovery would be shared with an unnamed litigation funder.
FDA Yet to Respond
As of publication, the FDA had not publicly responded to the latest fee request.
The court will now determine whether the agency’s handling of the FOIA request justifies requiring taxpayers to reimburse the plaintiffs’ legal expenses.
Legal experts note that prevailing parties in FOIA litigation can recover attorneys’ fees under certain circumstances, particularly when courts conclude that a lawsuit substantially caused the release of requested government records.
Pfizer Was Not the Defendant
Although the lawsuit centered on records concerning the Pfizer-BioNTech vaccine, Pfizer itself was not the defendant.
Instead, the litigation targeted the FDA’s handling of public records requests.
Reuters reported that Pfizer participated in portions of the case to protect confidential commercial information and trade secrets contained within some documents scheduled for release.
Why This Case Matters
The lawsuit has become one of the most closely watched FOIA cases in recent years because it highlights the tension between:
- Government transparency
- Protection of confidential commercial information
- Public interest during a national health emergency
- Administrative capacity to process massive records requests
Regardless of where readers stand on COVID-19 policy debates, the legal issues raised by the case extend far beyond vaccines.
The court’s eventual decision on attorneys’ fees may influence how federal agencies respond to future large-scale public records requests and could affect incentives for organizations considering FOIA litigation.
Key Takeaways
- A transparency group is asking a federal judge to order the FDA to pay over $867,000 in legal fees.
- The request follows a successful lawsuit that forced accelerated release of COVID-19 vaccine approval records.
- More than 1.8 million pages of documents have been disclosed.
- Pfizer was not the defendant but participated to protect proprietary information.
- The court’s ruling could shape future Freedom of Information Act litigation involving federal agencies.
Conclusion
What began as a dispute over access to vaccine approval documents has evolved into a broader debate about government accountability, public access to information, and the financial consequences when federal agencies resist disclosure.
The upcoming ruling on attorneys’ fees will be watched closely by transparency advocates, government lawyers, and public-interest organizations alike, as it may influence how future FOIA battles are fought—and who ultimately pays the bill.
